Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$175 Mln
P/E Ratio
8.36
P/B Ratio
1.59
Industry P/E
--
Debt to Equity
0
ROE
0.26 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
--
CFO
€-336.22 Mln
EBITDA
€-275.05 Mln
Net Profit
€-357.67 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
GENFIT S.A. - ADR
| -3.90 | -1.11 | 2.88 | 4.69 | -4.28 | -29.47 | -- |
|
BSE Sensex*
| 1.72 | 3.50 | 4.95 | 8.90 | 11.18 | 21.04 | 11.14 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
|
|---|---|---|---|---|---|
|
GENFIT S.A. - ADR
| -3.48 | -12.28 | -12.22 | 4.17 | -75.88 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients... with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France. Address: Parc EurasantE, Loos, France, 59120 Read more
Co-Founder & Chairman of the Board
Mr. Jean-Francois Mouney
Co-Founder & Chairman of the Board
Mr. Jean-Francois Mouney
Headquarters
Loos
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of GENFIT SA - ADR stood at $ 331 Mln as on 30-Jun-24
The share price of GENFIT SA - ADR is $3.57 (NASDAQ) as of 21-Apr-2025 16:00 EDT. GENFIT SA - ADR has given a return of -4.28% in the last 3 years.
GENFIT SA - ADR has a market capitalisation of $ 175 Mln as on 21-Apr-2025. As per Value Research classification, it is a company.
The P/B ratio of GENFIT SA - ADR is 1.59 times as on 21-Apr-2025, a 31% discount to its peers’ median range of 2.30 times.
The P/E ratio of GENFIT SA - ADR is 8.36 times as on 21-Apr-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the GENFIT SA - ADR and enter the required number of quantities and click on buy to purchase the shares of GENFIT SA - ADR.
Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France. Address: Parc EurasantE, Loos, France, 59120
The CEO & director of Mr. Jean-Francois Mouney. is GENFIT SA - ADR, and CFO & Sr. VP is Mr. Jean-Francois Mouney.
There is no promoter pledging in GENFIT SA - ADR.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| GENFIT S.A. - ADR | Ratios |
|---|---|
|
Return on equity(%)
|
40.42
|
|
Operating margin(%)
|
37.3
|
|
Net Margin(%)
|
29.95
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of GENFIT SA - ADR was $0 Mln.
$0.06
(
